Nexstim - med hjärnstimulering till världsherravälde

Det här företaget har väckt ganska mycket diskussion bland investerare i Finland och nu finns det en färsk analys av det. :slight_smile:

image

Nexstim published its Q1 business update on Friday. The company reported that it delivered two NBS systems during the period. Deliveries were slightly below our expectations in a seasonally slow start to the year. Based on the new data, we are modestly lowering our forecasts for the coming years. There have been no material changes in the valuation picture of the share. The stock is cheaply priced, but the risks are also elevated due to low visibility and a tight financial situation.